SERPINA1 and liver disorder: Cemdisiran (Fig. 4f) and ALN-AAT02 are two programs developed by Alnylam for the treatment of complement-mediated diseases and AAT deficiency-associated liver disease (alpha-1 liver disease) and function by targeting the C5 component of the complement pathway and alpha-1 antitrypsin (AAT), respectively.